Fig. 1 · Structure

Documents & Downloads

Foscenvivint (PRI-724)

Cat. No. A15856 CAS 1422253-38-0

CBP/beta-catenin antagonist

PRI-724 is the second-generation, potent and specific inhibitor of CBP/β-Catenin complex, and a modulator of the β-Catenin dependent canonical Wnt signaling pathway in cancer stem cells.

In Stock

Publications for Foscenvivint

1 publication citing this product

  1. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PRI-724 reduced TCF/β-catenin reporter activity in soft-tissue sarcoma cells, with the clearest response in AW cells. Nuclear β-catenin persisted after treatment. These findings support functional modulation of β-catenin-dependent transcription; they do not provide a biochemical binding constant or establish target selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Wnt/β-catenin 150 nM

Foscenvivint (PRI-724) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Foscenvivint (PRI-724) from 2 published references.

Foscenvivint (PRI-724) In Vitro Studies

In a nine-culture soft-tissue sarcoma panel, PRI-724 reduced viability below 50% of vehicle in seven cultures after 48 h over a 0.1–50 µM test range. SW684 and ICP020 did not reach 50% inhibition. The response was model-dependent and should not be interpreted as a universal potency value. [1]

Variable PRI-724 sensitivity across soft-tissue sarcoma cultures

Cell-based study · Nine human soft-tissue sarcoma cell lines/primary cultures: 93T449, AW, HT-1080, CP0024, SW982, SW872, SK-UT-1, SW684 and ICP020. [1]

PRI-724 reduced colorimetric viability with heterogeneous sensitivity. Seven of nine cultures fell below 50% of vehicle viability after 48 h; SW684 and ICP020 did not reach 50% inhibition over the tested range.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cultures with viability below 50% of vehicle at 48 hculture response count 7/9 (77.8%); SW684 and ICP020 did not reach 50% inhibition at tested concentrations[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–50 µM
Exposure duration
48 h
Method
Exposure followed by CellTiter 96 AQueous One Solution viability readout at 490 nm, normalized to vehicle-treated cultures.
Vehicle
DMSO vehicle control; final percentage not specified in the read main-text methods.
Reported limits
Individual IC50 values in Table S1 were not acquired. The paper labels the method MTT while naming CellTiter 96 AQueous One Solution; the reagent name is preserved here.
Methods and source locations

Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724

Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.

Results 2.1; Figure 1b and caption; Methods 4.1–4.2 and 4.11

Cultures with viability below 50% of vehicle at 48 h: Colorimetric viability; Figure 1b reports mean ± SEM from three independent experiments performed in triplicate. — Results 2.1; Figure 1b and caption; Methods 4.1–4.2

Transcriptional response with persistent nuclear β-catenin

Cell-based study · TCF reporter: HT-1080, 93T449 and AW cells; fractionation: these cells plus CP0024 and SK-UT-1. [1]

PRI-724 lowered TCF/β-catenin reporter activity, most clearly in AW cells, while nuclear β-catenin was not reduced by the fractionation/localization assessment. These experiments support a functional pathway effect; they do not measure binding affinity or independently establish target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TCF/β-catenin reporter activity relative to vehiclequalitative response Reported reductions of about 20% in HT-1080 and 93T449 and 50% in AW; Figure 2a marks statistical significance only for AW (** p < 0.01).[1]
Nuclear β-catenin abundance/localizationqualitative response No reduction in nuclear β-catenin reported across the tested STS cultures at 48 h.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
Reporter: Results 2.3 describes 24 h treatment; Figure 2a caption describes treatment and transfection followed by another 24 h. Exact sequencing is not resolved. Fractionation/localization: 48 h.
Method
TOP/FOPFLASH reporter system with firefly/Renilla normalization; nuclear/cytoplasmic immunoblotting and immunofluorescence.
Vehicle
DMSO-treated controls; final percentage not specified in the read main-text methods.
Reported limits
Reporter timing differs between narrative/methods and caption; no precise total exposure is inferred. Supplementary Figures S3/S4 were not acquired; no numerical claim from them is adopted.
Methods and source locations

Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724

Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.

Results 2.3; Figure 2a–c and caption; Methods 4.1, 4.6–4.7, 4.9 and 4.11

TCF/β-catenin reporter activity relative to vehicle: Dual luciferase, firefly normalized to Renilla; Figure 2a mean ± SEM of two independent experiments in triplicate. — Results 2.3; Figure 2a and caption; Methods 4.9

Nuclear β-catenin abundance/localization: Fractionation immunoblot with α-tubulin and PARP as cytoplasmic/nuclear markers; at least three independent experiments; immunofluorescence provides supporting localization images. — Results 2.3; Figure 2b–c and caption; Methods 4.6–4.7

Foscenvivint (PRI-724) In Vivo Studies

In male C57BL/6 mice, PRI-724 reduced liver collagen deposition during concurrent CCl4 injury and accelerated histological resolution after injury withdrawal. The reported regimen was 0.4 mg/mouse intraperitoneally four times weekly. ALT elevation was unchanged in the concurrent-injury experiment, and the resolution study showed no significant difference at one week. These are preclinical, model-specific findings. [2]

Reduced fibrogenesis during concurrent liver injury

Animal study · Male C57BL/6 mice, 8–11 weeks old; CCl4-induced liver fibrosis. [2]

Concurrent PRI-724 treatment reduced Sirius Red-positive collagen area and αSMA staining in male C57BL/6 mice. Serum ALT elevation was not reduced, limiting an interpretation based on protection from hepatocellular injury.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liver collagen deposition and αSMA stainingqualitative response Reduced versus CCl4 + PBS controls; Figure 1 indicates P < 0.05 for the corresponding quantified staining comparisons.[2]
Serum ALT elevation during CCl4 exposurequalitative response Not affected by PRI-724 according to Results 3.1; Supplementary Figure 1B shows overlapping responses.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Four times weekly
Treatment course
4 weeks, concurrent with CCl4 exposure
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PRI-724 versus PBS
0.4 mg/mouse
CCl4 + PBS; mineral-oil control shown in Figure 1.Concurrent PRI-724 treatment reduced Sirius Red-positive collagen area and αSMA staining in male C57BL/6 mice. Serum ALT elevation was not reduced, limiting an interpretation based on protection from hepatocellular injury.[2]
PRI-724 versus PBS
Model: Male C57BL/6 mice, 8–11 weeks old; CCl4-induced liver fibrosis.
Reported limits: No conversion to mg/kg. Figure captions report independent experiments rather than an explicit per-group animal n.
Methods and source locations

Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724

Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.

Methods 2.1 and 2.5; Results 3.1; Figure 1 and caption; Supplementary Figure 1B

Liver collagen deposition and αSMA staining: Sirius Red and αSMA immunohistochemistry; Figure 1 caption reports mean ± SD from at least 3 independent experiments; 2-tailed Student’s t-test. — Figure 1B and caption; Results 3.1

Serum ALT elevation during CCl4 exposure: Serum ALT comparison; no numerical ALT estimates extracted. — Results 3.1; Supplementary Figure 1B and caption

PRI-724 versus PBS · Methods 2.1 and 2.5; Results 3.1; Figure 1 and caption; Supplementary Figure 1B

Accelerated collagen resolution after injury withdrawal

Animal study · Male C57BL/6 mice, 8–11 weeks old; CCl4-induced liver fibrosis. [2]

After eight weeks of CCl4 exposure, PRI-724 accelerated reduction of collagen deposition at the two-week resolution endpoint. The authors report no significant difference at one week (data not shown).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Sirius Red-positive liver area during resolutionqualitative response Lower with PRI-724 than PBS at two weeks (Figure 4A, P < 0.05); no significant difference at one week reported in text (data not shown).[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Four times weekly
Treatment course
Started three days after the last CCl4 injection; two-week resolution window after eight weeks of injury
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PRI-724 versus PBS
0.4 mg/mouse
PBS after withdrawal of CCl4; end-of-injury baseline shown in Figure 4.After eight weeks of CCl4 exposure, PRI-724 accelerated reduction of collagen deposition at the two-week resolution endpoint. The authors report no significant difference at one week (data not shown).[2]
PRI-724 versus PBS
Model: Male C57BL/6 mice, 8–11 weeks old; CCl4-induced liver fibrosis.
Reported limits: No conversion to mg/kg. Figure captions report independent experiments rather than an explicit per-group animal n.
Methods and source locations

Compound reported in the paper: PRI-724; Compound label in the paper: PRI-724

Applies to the paper’s named PRI-724 material and specified model. No Adooq lot validation, salt conversion or independent stereochemical equivalence is claimed.

Methods 2.1 and 2.5; Results 3.4; Figure 4 and caption

Sirius Red-positive liver area during resolution: Sirius Red histology; Figure 4 caption reports mean ± SD from at least 3 independent experiments and 2-tailed Student’s t-test. — Results 3.4 first paragraph; Figure 4A and caption

PRI-724 versus PBS · Methods 2.1 and 2.5; Results 3.4; Figure 4 and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1422253-38-0
Applications CBP/beta-catenin antagonist
Formula C33H35N6O7P
Molecular Weight 658.64
Synonyms PRI 724
SMILES
CC1C2N(C(C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Foscenvivint (PRI-724) Research References

  1. [1] Martinez-Font E, Pérez-Capó M, Ramos R, et al. Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas Cancers (2020). PMID: 32911761 DOI: 10.3390/cancers12092556 Source material
  2. [2] Osawa Y, Oboki K, Imamura J, et al. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice EBioMedicine (2015). PMID: 26870800 DOI: 10.1016/j.ebiom.2015.10.010 Source material

Publications

1 publication citing this product

  1. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682

Added to your cart

View Cart Checkout
Loading...